https://pharmaboardroom.com/interviews/alex-zhavoronkov-ceo-insilico-medicine/ https://pharmaboardroom.com/interviews/alex-zhavoronkov-ceo-... Besides Aspuru-G

https://pharmaboardroom.com/interviews/alex-zhavoronkov-ceo-insilico-medicine/ https://pharmaboardroom.com/interviews/alex-zhavoronkov-ceo-... Besides Aspuru-Guzik, this author seems to be the most wellknown in the field. My read is that they are in HK for the diverse CS talent (ie other russians) and second, better funding options compared to being in China proper. Knowing russians, they have been considering the Far East as more culturally accomodating than the SV corporate style (combining the poorer aspects of left and right) for some time now. I would say if Texas had a insilico pharm industry that might be comparable to HK..